Ordovas J M, Civeira F, Genest J, Craig S, Robbins A H, Meade T, Pocovi M, Frossard P M, Masharani U, Wilson P W
Lipid Metabolism Laboratory, USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111.
Atherosclerosis. 1991 Mar;87(1):75-86. doi: 10.1016/0021-9150(91)90234-t.
Data from various laboratories have indicated associations of various alleles determined by RFLPs within or adjacent to several apolipoprotein genes with abnormalities in plasma lipids and/or premature coronary artery disease (CAD). In order to assess such relationships we have examined allele frequencies of 8 different RFLPs within or adjacent to the apo A-I, C-III and A-IV gene complex on the long arm of chromosome 11 (MspI, 5' to the apo A-I gene; MspI, within the apo A-I gene; PstI, 3' to the apo A-I gene; SstI, 3' to the apo C-III gene; PvuII, within the apo C-III gene; PvuII, 5' to the apo C-III gene; XbaI, within the apo A-IV gene; and XbaI, 3' to the apo A-IV gene) in 202 patients with CAD (50% narrowing of one or more coronary arteries) prior to age 60 and 145 normal controls. None of the allele frequencies of these RFLPs were significantly different in cases as compared to controls. With regard to associations with plasma lipids and apolipoprotein levels, the rare allele determined by the absence of the PstI site was associated with elevated triglyceride levels (P less than 0.05) in cases, but not in controls. In contrast, the rate MspI allele 5' to the apo A-I gene was associated with elevated triglyceride levels (P less than 0.05) in controls but not in cases. In both cases and controls, subjects with the uncommon SstI allele had triglyceride levels that were 9 and 38% higher than in those without this allele. These differences were significant (P less than 0.05) only in controls. Our data indicate that the rare allele determined by the SstI site within this gene complex deserves further study in order to understand its association with elevated triglycerides in Caucasian populations. However, at the present time all these DNA markers lack sufficient specificity to be clinically useful for CAD risk assessment.
来自不同实验室的数据表明,由几种载脂蛋白基因内部或相邻区域的限制性片段长度多态性(RFLP)所确定的各种等位基因,与血脂异常和/或早发性冠状动脉疾病(CAD)有关。为了评估此类关系,我们检测了位于11号染色体长臂上载脂蛋白A-I、C-III和A-IV基因复合体内部或相邻区域的8种不同RFLP(apo A-I基因5'端的MspI;apo A-I基因内部的MspI;apo A-I基因3'端的PstI;apo C-III基因3'端的SstI;apo C-III基因内部的PvuII;apo C-III基因5'端的PvuII;apo A-IV基因内部的XbaI;apo A-IV基因3'端的XbaI)的等位基因频率,这些检测对象包括202例60岁之前患有CAD(一条或多条冠状动脉狭窄50%)的患者以及145名正常对照者。与对照组相比,这些RFLP的等位基因频率在病例组中均无显著差异。关于与血脂和载脂蛋白水平的关联,由PstI位点缺失所确定的罕见等位基因与病例组中甘油三酯水平升高相关(P<0.05),而在对照组中则无此关联。相反,apo A-I基因5'端的常见MspI等位基因与对照组中甘油三酯水平升高相关(P<0.05),但在病例组中无此关联。在病例组和对照组中,具有罕见SstI等位基因的受试者甘油三酯水平比没有该等位基因的受试者分别高9%和38%。这些差异仅在对照组中具有统计学意义(P<0.05)。我们的数据表明,该基因复合体内由SstI位点所确定的罕见等位基因值得进一步研究,以了解其与白种人群甘油三酯升高的关联。然而,目前所有这些DNA标记物均缺乏足够的特异性,无法在临床上用于CAD风险评估。